Weight-loss drug developers line up to tap lucrative market as competition heats up

Published on 2025-05-16 at 13:54

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Amgen Inc.

Amgen Inc., Q1 2025 Earnings Call, May 01, 2025	07-11
HSBC Adjusts Price Target on Amgen to $337 From $346, Maintains Buy Rating	07-11	MT
Major deals involving U.S. drugmakers and biotechs over the past decade	07-09	RE
Crescent Biopharma, Inc. Appoints Jan Pinkas as Chief Scientific Officer	07-08	CI
Nasdaq closes lower, weighed by tech stocks, Dow ends sharply higher	07-01	RE
S&P 500, Nasdaq turn higher as Senate passes Trump's tax cut bill	07-01	RE
S&P 500, Nasdaq edge down as Tesla slides, data backs Fed patience	07-01	RE
Outlook Therapeutics, Inc. Appoints Bob Jahr to Board of Directors	07-01	CI
Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factory Receivetor 2B Positive First-Line Gastric	06-30	CI
Amgen says gastric cancer drug meets main goal in late-stage trial	06-30	RE
Amgen Says Bemarituzumab Plus Chemo Phase 3 Gastric Cancer Study Met Overall Survival Primary Endpoint	06-30	MT
Amgen Meets Primary Endpoint in Phase 3 Trial of Gastric Cancer Treatment	06-30	DJ
Amgen's gastric cancer drug meets late-stage trial goal	06-30	RE
Amgen Inc. Presents at Citi's 2025 Virtual Oncology Leadership Summit, Feb-19-2025 03:00 PM	06-30
Nektar's lead drug candidate shows promise in eczema trial, shares soar	06-24	RE
Global markets live: Tesla, Google, Amazon, Amgen, Eni…	06-24
HSBC Adjusts Price Target on Amgen to $346 From $357	06-24	MT
Amgen Reports Up to 20% Weight Loss With Monthly MariTide in Phase 2 Obesity Study	06-24	MT
Amgen Inc. - Special Call	06-23
Amgen experimental weight-loss drug needs lower dose to limit side effects	06-23	RE
Amgen Expands MariTide Development Plans After Weight-Loss Trial -- Update	06-23	DJ
Amgen Expands MariTide Development Plans After Successful Weight-Loss Trial	06-23	DJ
Low start dose of Amgen experimental weight-loss drug limits side effects	06-23	RE
Amgen Announces Full Results from Part 1 of the Phase 2 Study of MariTide	06-23	CI
Galapagos NV Announces Chief Financial Officer Changes	06-23	CI